These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Moral decay at GSK reaps record US$3 billion fine. Lancet; 2012 Jul; 380(9836):2. PubMed ID: 22770442 [No Abstract] [Full Text] [Related]
43. Truth, Falsity, and Fraud: Off-Label Drug Settlements and the Future of the Civil False Claims Act. Krause JH Food Drug Law J; 2016; 71(3):401-40. PubMed ID: 29140064 [TBL] [Abstract][Full Text] [Related]
44. A defense of the learned intermediary doctrine. Goetz RB; Growdon KR Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470 [No Abstract] [Full Text] [Related]
45. Dismissal of investor fraud claim over HIV drug reversed. AIDS Policy Law; 2008 Nov; 23(12):8. PubMed ID: 19145698 [No Abstract] [Full Text] [Related]
46. Drug review "behind the curtain": a response to Professor Struve. O'Reilly JT Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971 [No Abstract] [Full Text] [Related]
47. The learned intermediary doctrine: past, present and future. Alsobrook HB Leg Med; 1994; ():269-80. PubMed ID: 7830482 [No Abstract] [Full Text] [Related]
48. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development. Lee VH Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258 [No Abstract] [Full Text] [Related]
49. GlaxoSmithKline pays $3bn to settle dispute over rosiglitazone and other drugs. Hawkes N BMJ; 2011 Nov; 343():d7234. PubMed ID: 22065678 [No Abstract] [Full Text] [Related]
50. The case for preemption of prescription drug failure-to-warn claims. Kim CH Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969 [No Abstract] [Full Text] [Related]
51. GSK faces accusations of bribing doctors in Poland. Jofre S BMJ; 2014 Apr; 348():g2768. PubMed ID: 24733722 [No Abstract] [Full Text] [Related]
52. Pfizer to pay $430 million over promoting drug to doctors. Harris G N Y Times Web; 2004 May; ():C6. PubMed ID: 15290803 [No Abstract] [Full Text] [Related]
53. Four US drug companies pay $124m for defrauding Medicaid. Tanne JH BMJ; 2009 Oct; 339():b4500. PubMed ID: 19875428 [No Abstract] [Full Text] [Related]
54. Indian patients go to court over cancer drug. Murdur G BMJ; 2004 Aug; 329(7463):419. PubMed ID: 15321889 [No Abstract] [Full Text] [Related]
55. Court rules that FDA cannot restrict off-label marketing. Roehr B BMJ; 2015 Aug; 351():h4367. PubMed ID: 26265632 [No Abstract] [Full Text] [Related]
56. AstraZeneca must pay €52.5m fine for anticompetitive tactics, rules European court. Hawkes N BMJ; 2012 Dec; 345():e8396. PubMed ID: 23230222 [No Abstract] [Full Text] [Related]
57. Deterring the importation of counterfeit pharmaceutical products. Stearn DW Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351 [No Abstract] [Full Text] [Related]
58. EMEA approves OGS drug rejected by FDA. Mitchell P Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490 [No Abstract] [Full Text] [Related]
59. Lessons learned from good manufacturing practice noncompliance. Peskoe MP Food Drug Law J; 1995; 50(1):65-70. PubMed ID: 10342986 [No Abstract] [Full Text] [Related]
60. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions. Chodock R; Yolkut D; Connolly DR Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]